Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 4Thymus Neoplasms 1Rhabdomyosarcoma 1Pheochromocytoma 1Paraganglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Meningioma 1Lymphoma 1Gastro-enteropancreatic neuroendocrine tumor 1Central Nervous System Neoplasms 1

Interventions

gallium Ga 68 dotatate 4lutetium Lu 177 dotatate 2belzutifan 2Fluorodeoxyglucose F18 23-fluorobenzylguanidine 2olaparib 1fluorodopa F 18 1fludarabine phosphate 1Specimen Handling 1Phenoxybenzamine 1Magnetic Resonance Spectroscopy 1Interleukin-13 1Genetic Testing 1Cyclophosphamide 1Blood Specimen Collection 1Biopsy 16-fluorodopamine 13-Iodobenzylguanidine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pheochromocytoma × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all
NCT06045260 2024-08-13

LUFOR

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting
100 enrolled
CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡